Inactive Instrument

Skinvisible Inc Stock OTC Bulletin Board

Equities

US8307031042

Personal Products

Sales 2022 279K Sales 2023 20K Capitalization 380K
Net income 2022 -1M Net income 2023 -2M EV / Sales 2022 14.7 x
Net Debt 2022 3.63M Net Debt 2023 6.15M EV / Sales 2023 327 x
P/E ratio 2022
-0.37 x
P/E ratio 2023
-0.16 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 96.6%
More Fundamentals * Assessed data
Dynamic Chart
Skinvisible, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Skinvisible, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Skinvisible, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Skinvisible, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Skinvisible, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Skinvisible, Inc. Auditor Raises 'Going Concern' Doubt CI
Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Skinvisible, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Skinvisible, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Skinvisible, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
Managers TitleAgeSince
Chief Executive Officer 75 98-03-04
Public Communications Contact 61 -
Members of the board TitleAgeSince
Chief Executive Officer 75 98-03-04
Director/Board Member 51 17-09-21
More insiders
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
More about the company